Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 5/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | PARP1 | P09874 | 3/20 | 0.64 |
| ▸ | HTR1A | P08908 | 4/20 | 0.62 |
| ▸ | HTR7 | P34969 | 4/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394834 | 0.92 | DRD4 (0.84) | DRD4GAATSHRHSD17B10ALDH1A1 | |
| SCHEMBL3399978 | 0.88 | DRD4 (1.00) | DRD4GAATSHRHSD17B10ALDH1A1 | |
| SCHEMBL3400090 | 0.87 | DRD4 (0.77) | DRD4GAATSHRHSD17B10ALDH1A1 | |
| SCHEMBL19002890 | 0.87 | DRD4 (0.77) | DRD4GAATSHRHSD17B10ALDH1A1 | |
| SCHEMBL14585685 | 0.86 | GAA (0.78) | DRD4GAATSHRHSD17B10ALDH1A1 | |
| SCHEMBL3399004 | 0.84 | GAA (1.00) | DRD4GAATSHRHSD17B10ALDH1A1 | |
| SCHEMBL4814328 | 0.83 | NPC1 (1.00) | DRD4GAAALDH1A1NPC1HTR1A | |
| SCHEMBL3397598 | 0.82 | DRD4 (0.78) | DRD4GAATSHRHSD17B10ALDH1A1 | |
| SCHEMBL13281130 | 0.81 | GAA (0.71) | DRD4GAATSHRHSD17B10ALDH1A1 | |
| SCHEMBL4631962 | 0.81 | GAA (0.71) | DRD4GAATSHRHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697206-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S A (LU) | 2019-04-03 | — | — | EP | disclosed |
| EP-2697206-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S A (LU) | 2019-04-03 | — | — | EP | disclosed |
| US-9353067-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2016-05-31 | — | — | US | disclosed |
| US-9353067-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2016-05-31 | — | — | US | disclosed |
| US-9353067-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2016-05-31 | — | — | US | disclosed |
| US-20140296247-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. | 2014-10-02 | — | — | US | disclosed |
| US-20140296247-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. | 2014-10-02 | — | — | US | disclosed |
| US-20140296247-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. | 2014-10-02 | — | — | US | disclosed |
| EP-2697206-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | Atir Holding S.A. (LU) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012140642-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012140642-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296247-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | CYP19A1, HSD17B11, SHBG | DRD4 282/4885GAA 719/4885TSHR 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.